Significance Of Expression Of Serotransferrin In Small Cell Lung Cancer

Objective：Detect the expression of serotransferrin(TF) in plasma ofpatients with small cell lung cancer(SCLC), compared with the clinicalrecognized SCLC tumor marker-neuron specific enolase(NSE), andinvestigate the revelance between TF and NSE and its clinical significance ofthe joint inspection.Methods：The research include13patients with SCLC and7healthyadults, separated into3groups: before-chemotherapy group, after–chemo-therapy group and normal control group. Western blot method assay theexpression on protein level of TF. Using immunohistochemical method todetect patients with small cell lung cancer of TF expression in carcinomatissue specimens of paraffin, and contrast TF with traditional tumor markersNSE in the diagnosis of NSE application.Results：1Using western blot method to analyse the expression of TF in plasma:The expression of TF in plasma of patients with SCLC is lower than thenormal control group, and the difference has statistical significance（P=0.000，P＜0.05）. The expression of TF in before-chemotherapy group is lower thanthe normal control group, and the difference has statistical significance（P=0.000，P＜0.05）. The expression of TF in after-chemotherapy group isalso lower than the normal control group, and the difference has statisticalsignificance（P=0.000，P＜0.05）.Level of plasma TF in after-chemotherapy group of SCLC patients ishigher than that before treatment, but there was no statistically significantdifference.And in the same patient, the level of plasma TF inafter-chemotherapy group is higher than that before-chemotherapy group. Dueto the matching sample size is less, follow-up still need to further expand the sample size (especially the same before and after chemotherapy in patientswith paired samples).2TF, NSE, Hb expression in SCLC relevance: TF and NSE expression inSCLC was no correlation(r=0.068, P>0.05), TF expression with no correlationwith Hb(r=-0.043,P>0.05).TF expression and no correlation withPRO2619(r=-0.01, P>0.05). Follow-up still need to further expand the samplesize.3Using western blot method to analyse the expression of TF in thecarcinoma group, pneumonia group and normal tissue: TF expression inSCLC was significantly lower than pneumonia group and normal tissue, tofurther validate the western blot results.Conclusions：1The expression of TF in plasma of patients with SCLC is lower than thenormal control group, prompted TF is possible related with the onset of SCLCas a potential serum marker. The level of plasma TF in after-chemotherapygroup is higher than that before-chemotherapy group, in the same patient,Which prompt TF may be associated with SCLC patients’ tumour conditionchanges.2TF and NSE expression in patients with SCLC was no correlation(r=0.068, P>0.05). Given the limitations of small sample size and statisticalmethod, for further infer that the overall degree of close correlation need alarger sample size. TF and Hb expression in patients with SCLC was nocorrelation (r=-0.053, P>0.05). Due to the number of cases is less, andselected cases patients were no anemia status, the sample lack ofcomprehensiveness, therefore TF and the correlation of tumor anemia needfurther research.3TF expression in SCLC was significantly lower than pneumonia groupand normal tissue, to further validate the western blot results.